Open in Screener

DYN

Dyne Therapeutics Inc

Apr 02 • 04:00PM ET

18.84

+0.74 4.09 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: VTI XBI IWM VB VXF IBB VBR IWN SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.54	Insider Own	27.21%	Shs Outstand	164.95M	Perf Week	1.56%
Market Cap	3.11B	Forward P/E	-	EPS next Y	-3.09	Insider Trans	-1.80%	Shs Float	120.12M	Perf Month	23.70%
Enterprise Value	2.17B	PEG	-	EPS next Q	-0.77	Inst Own	91.33%	Short Float	15.90%	Perf Quarter	-3.68%
Income	-446.21M	P/S	-	EPS this Y	8.96%	Inst Trans	10.31%	Short Ratio	8.52	Perf Half Y	50.72%
Sales	0.00M	P/B	3.20	EPS next Y	2.11%	ROA	-47.52%	Short Interest	19.10M	Perf YTD	-3.68%
Book/sh	5.89	P/C	2.80	EPS next 5Y	13.20%	ROE	-55.71%	52W High	25.00 -24.64%	Perf Year	90.11%
Cash/sh	6.73	P/FCF	-	EPS past 3/5Y	-2.41% 3.39%	ROIC	-39.27%	52W Low	6.36 196.23%	Perf 3Y	63.54%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.74% 7.39%	Perf 5Y	18.19%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.72%	Oper. Margin	-	ATR (14)	1.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.48	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	22.25	EPS Q/Q	13.34%	SMA20	4.29%	Beta	1.21	Target Price	38.19
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	9.61%	Rel Volume	0.86	Prev Close	18.10
Employees	258	LT Debt/Eq	0.17	Earnings	Mar 02 BMO	SMA200	20.65%	Avg Volume	2.24M	Price	18.84
IPO	Sep 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.34% -	Trades		Volume	1,939,705	Change	4.09%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$40
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15

Show Previous Ratings

Apr-01-26 07:30AM	Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines (GlobeNewswire)
Mar-10-26 09:47PM	Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade (Insider Monkey) +11.81%
Mar-08-26 06:01PM	Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
06:00PM	Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Mar-02-26 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
05:52AM	Loading…
Feb-26-26 05:52AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
Feb-25-26 07:30AM	Dyne Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-22-26 04:00PM	Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-18-26 07:38PM	Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan (Insider Monkey)
Feb-16-26 12:23PM	Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry (Insider Monkey)
Jan-27-26 09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-20-26 07:30AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-15-26 11:35AM	Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) (Insider Monkey) -5.90%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 07:30AM	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.01%
07:30AM	Loading…
Dec-23-25 07:30AM	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire)
Dec-22-25 06:50AM	Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) (Insider Monkey)
Dec-11-25 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
07:44AM	Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial (Insider Monkey)
Dec-10-25 06:20PM	Why Dyne Therapeutics Stock Was a Big Winner on Wednesday (Motley Fool) +6.78%
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
Dec-09-25 09:42PM	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock (GlobeNewswire) -16.94%
06:42PM	Why Dyne Therapeutics Stock Tanked on Tuesday (Motley Fool)
04:54PM	Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More (Motley Fool)
02:22PM	Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate (Insider Monkey)
01:34PM	Dyne to seek accelerated approval of DMD drug on Phase I/II data (Clinical Trials Arena)
Dec-08-25 04:02PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +9.47%
03:07PM	Why Dyne Therapeutics Stock Was Blasting Higher Today (Motley Fool)
06:30AM	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
11:00AM	Loading…
Dec-07-25 11:00AM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET (GlobeNewswire)
Nov-30-25 12:26AM	Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release (Insider Monkey)
Nov-21-25 03:43PM	Why Dyne Therapeutics Stock Was Crushing it This Week (Motley Fool) +5.27%
Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -12.89%
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)
04:10PM	Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer (GlobeNewswire)
Mar-16-25 07:00PM	Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months (GlobeNewswire)
Mar-12-25 03:05PM	Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks (Benzinga)
01:12PM	BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating (GuruFocus.com)
Mar-11-25 07:30AM	Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-27-25 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-14-25 04:05PM	Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-13-25 09:35AM	After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) (Zacks)
Feb-06-25 09:39AM	Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey) +6.89%
Feb-03-25 07:30AM	Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 09:35AM	Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround (Zacks)
Jan-21-25 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-10-25 06:30AM	Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 (GlobeNewswire) -31.15%
Jan-09-25 07:30AM	Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET (GlobeNewswire) -31.15%
Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lucera Erick	Chief Financial Officer	Apr 01 '26	Sale	18.64	5,727	106,751	125,373	Apr 03 04:10 PM
Posner Brian S	Director	Mar 30 '26	Buy	17.08	2,000	34,160	15,500	Apr 01 04:27 PM
Lucera Erick	Officer	Apr 01 '26	Proposed Sale	18.64	5,727	106,758		Apr 01 04:06 PM
Posner Brian S	Director	Mar 11 '26	Buy	19.35	2,000	38,700	13,500	Mar 13 04:46 PM
Kersten Dirk	Director	Mar 11 '26	Sale	19.52	129,672	2,530,562	4,644,386	Mar 13 04:35 PM
Kersten Dirk	Director	Mar 10 '26	Sale	19.57	511,098	10,000,327	4,774,058	Mar 11 05:27 PM
Kersten Dirk	Director	Mar 09 '26	Sale	17.72	177,690	3,148,987	5,285,156	Mar 11 05:27 PM
ForDyne B.V.	Affiliate	Mar 11 '26	Proposed Sale	19.75	807,295	15,944,076		Mar 11 04:05 PM
Posner Brian S	Director	Mar 06 '26	Buy	15.06	3,000	45,180	11,500	Mar 10 05:33 PM
ForDyne B.V.	Affiliate	Mar 09 '26	Proposed Sale	17.72	807,295	14,306,720		Mar 09 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Mar 05 '26	Sale	14.90	148	2,205	154,581	Mar 06 04:10 PM
Kerr Douglas	Chief Medical Officer	Mar 05 '26	Sale	14.90	904	13,470	171,606	Mar 06 04:09 PM
Cox John	CEO & President	Mar 05 '26	Sale	14.90	2,732	40,707	374,145	Mar 06 04:08 PM
Cox John	Officer	Mar 05 '26	Proposed Sale	14.90	2,732	40,707		Mar 05 04:06 PM
Kerr Douglas	Officer	Dec 05 '25	Proposed Sale	20.72	880	18,231		Dec 05 04:56 PM
Cox John	Officer	Dec 05 '25	Proposed Sale	20.72	2,662	55,150		Dec 05 04:55 PM
Cox John	CEO & President	Dec 05 '25	Sale	20.72	2,662	55,157	196,877	Dec 05 04:11 PM
Kerr Douglas	Chief Medical Officer	Dec 05 '25	Sale	20.72	880	18,234	87,510	Dec 05 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Dec 05 '25	Sale	20.72	144	2,984	94,729	Dec 05 04:08 PM
Cox John	CEO & President	Sep 05 '25	Sale	13.41	2,640	35,402	199,539	Sep 09 04:31 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 04 '25	Sale	13.27	894	11,863	95,017	Sep 08 04:06 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 05 '25	Sale	13.41	144	1,931	94,873	Sep 08 04:06 PM
Kerr Douglas	Chief Medical Officer	Sep 04 '25	Sale	13.27	3,552	47,135	89,263	Sep 08 04:03 PM
Kerr Douglas	Chief Medical Officer	Sep 05 '25	Sale	13.41	873	11,707	88,390	Sep 08 04:03 PM
Cox John	Officer	Sep 05 '25	Proposed Sale	13.41	2,640	35,404		Sep 05 04:14 PM
Kerr Douglas	Officer	Sep 04 '25	Proposed Sale	13.27	4,552	60,402		Sep 04 04:45 PM
Cox John	CEO & President	Jul 14 '25	Buy	9.11	100,000	911,000	242,179	Jul 15 05:11 PM
Scalzo Richard William	Officer	Jun 11 '25	Proposed Sale	14.75	1,330	19,619		Jun 11 04:30 PM
Beskrovnaya Oxana	Officer	Jun 11 '25	Proposed Sale	14.75	2,132	31,449		Jun 11 04:29 PM
Cox John	CEO & President	Jun 05 '25	Sale	13.35	4,060	54,201	142,179	Jun 06 04:07 PM
Kerr Douglas	Chief Medical Officer	Jun 05 '25	Sale	13.35	1,342	17,916	92,815	Jun 06 04:05 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 05 '25	Sale	13.35	146	1,949	95,911	Jun 06 04:03 PM
Kerr Douglas	Officer	Jun 05 '25	Proposed Sale	13.35	1,342	17,911		Jun 05 04:13 PM
Cox John	Officer	Jun 05 '25	Proposed Sale	13.35	4,060	54,186		Jun 05 04:11 PM
Scalzo Richard William	Officer	Jun 05 '25	Proposed Sale	13.35	914	12,198		Jun 05 04:09 PM
Beskrovnaya Oxana	Officer	Jun 05 '25	Proposed Sale	13.35	1,093	14,587		Jun 05 04:07 PM
Scalzo Richard William	Officer	May 16 '25	Proposed Sale	11.82	2,479	29,313		May 16 04:10 PM
Beskrovnaya Oxana	Officer	May 16 '25	Proposed Sale	11.82	2,589	30,614		May 16 04:09 PM

Open in Screener

EDIT

Editas Medicine Inc

Apr 02 • 04:00PM ET

2.67

+0.06 2.30 %

Healthcare • Biotechnology • USA • NASD

EDIT Editas Medicine Inc daily Stock Chart

Peers: CRSP NTLA BEAM BLUE SGMO VERV RARE PSTX CLLS QURE

| Held by: VTI IWM VXF IWN IBB SCHA VTWO IWC VHT SCHB

Index	RUT	P/E	-	EPS (ttm)	-1.88	Insider Own	0.52%	Shs Outstand	97.87M	Perf Week	15.09%
Market Cap	261.32M	Forward P/E	-	EPS next Y	-0.97	Insider Trans	-2.56%	Shs Float	97.37M	Perf Month	21.92%
Enterprise Value	191.38M	PEG	-	EPS next Q	-0.27	Inst Own	52.32%	Short Float	11.83%	Perf Quarter	30.24%
Income	-160.06M	P/S	6.45	EPS this Y	40.54%	Inst Trans	7.67%	Short Ratio	6.47	Perf Half Y	-24.79%
Sales	40.52M	P/B	9.58	EPS next Y	9.07%	ROA	-60.61%	Short Interest	11.52M	Perf YTD	30.24%
Book/sh	0.28	P/C	1.78	EPS next 5Y	15.70%	ROE	-198.14%	52W High	4.54 -41.15%	Perf Year	126.27%
Cash/sh	1.50	P/FCF	-	EPS past 3/5Y	17.49% 1.84%	ROIC	-172.17%	52W Low	0.91 193.37%	Perf 3Y	-63.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	27.15% -14.89%	Gross Margin	86.98%	Volatility	8.09% 9.00%	Perf 5Y	-93.77%
Dividend TTM	-	EV/Sales	4.72	EPS Y/Y TTM	34.67%	Oper. Margin	-245.15%	ATR (14)	0.19	Perf 10Y	-92.76%
Dividend Ex-Date	-	Quick Ratio	3.54	Sales Y/Y TTM	25.40%	Profit Margin	-395.01%	RSI (14)	64.05	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	3.54	EPS Q/Q	89.53%	SMA20	10.93%	Beta	2.11	Target Price	4.01
Payout	-	Debt/Eq	2.81	Sales Q/Q	-19.16%	SMA50	24.64%	Rel Volume	0.63	Prev Close	2.61
Employees	87	LT Debt/Eq	2.41	Earnings	Mar 09 BMO	SMA200	3.17%	Avg Volume	1.78M	Price	2.67
IPO	Feb 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	74.20% 196.33%	Trades		Volume	1,117,811	Change	2.30%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-25	Initiated	H.C. Wainwright	Buy	$3
Dec-16-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-13-24	Downgrade	Truist	Buy → Hold
Dec-13-24	Downgrade	Stifel	Buy → Hold	$11 → $3
Dec-13-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$7 → $4
Nov-25-24	Downgrade	BofA Securities	Buy → Underperform	$13 → $1
Nov-06-24	Upgrade	Evercore ISI	In-line → Outperform
Nov-04-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12

Show Previous Ratings

Mar-27-26 07:00AM	Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference (GlobeNewswire)
Mar-10-26 11:09AM	EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y (Zacks) +13.79%
Mar-09-26 08:15AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +16.00%
07:11AM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates (GlobeNewswire)
09:00AM	Loading…
Feb-23-26 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.59%
Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks) +6.56%
Nov-25-25 11:10AM	NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies (Zacks)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
Nov-21-25 10:15AM	AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo (Zacks)
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
Nov-14-25 09:40AM	Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-11-25 10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks) +5.56%
Nov-10-25 08:25AM	Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:24AM	Loading…
07:24AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Third Quarter 2025 Results and Business Updates (GlobeNewswire)
Nov-07-25 07:10AM	Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates (Zacks) -8.18%
Nov-06-25 06:10PM	Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-03-25 09:00AM	Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 05:15PM	Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-09-25 11:01AM	Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress (GlobeNewswire)
Oct-06-25 09:00AM	Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-29-25 12:56AM	Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program (Insider Monkey) +8.64%
Sep-25-25 09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
Sep-11-25 11:30AM	Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report? (Zacks) +5.86%
Sep-03-25 09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 07:00AM	Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate (GlobeNewswire)
Aug-28-25 04:01PM	Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate (GlobeNewswire)
Aug-27-25 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:50AM	Loading…
Aug-15-25 07:50AM	Why Editas Medicine Stock Was Skyrocketing This Week (Motley Fool)
Aug-13-25 07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire) +34.50%
Aug-12-25 05:15PM	Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:14PM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Editas Medicine Announces Second Quarter 2025 Results and Business Updates (GlobeNewswire)
03:00PM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Can This Beaten-Down Stock Bounce Back? (Motley Fool)
Aug-11-25 08:15AM	Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-30-25 05:40PM	MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-03-25 09:09AM	Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data (Insider Monkey)
Jun-28-25 05:04AM	Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? (Motley Fool)
Jun-27-25 08:15AM	2 Beaten-Down Stocks to Avoid (Motley Fool) +7.55%
Jun-17-25 10:07AM	Editas Medicine Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
Jun-12-25 02:01AM	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June (GlobeNewswire) +7.39%
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
May-25-25 06:00AM	1 Stock Down 97% That Could Double, According to Wall Street (Motley Fool)
May-15-25 07:30PM	Editas Medicine: A Cautionary Tale for Investors (Motley Fool) +8.24%
03:11AM	A new CFO tasked with taking scrappy Editas from last years layoffs into new gene editing territory (Pharma Voice)
May-14-25 09:31AM	Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June (GlobeNewswire) -8.00%
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-13-25 09:40AM	Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
07:01AM	Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-12-25 05:45PM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.21%
04:48PM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	Editas Medicine Announces First Quarter 2025 Results and Business Updates (GlobeNewswire)
04:01PM	Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board (GlobeNewswire)
12:00PM	Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-05-25 04:01PM	Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May (GlobeNewswire) -6.10% -13.64%
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
Apr-28-25 04:31PM	Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Apr-04-25 11:30AM	Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? (Zacks) -8.04%
Apr-03-25 10:48AM	Editas Medicine: Do The Risks Outweigh The Rewards? (Seeking Alpha) -5.08%
Mar-21-25 08:15AM	AstraZeneca deepens China investment; Editas loses CFO to Dyne (BioPharma Dive)
Mar-20-25 04:12PM	Editas Medicine promotes Amy Parison as CFO (SeekingAlpha)
04:01PM	Editas Medicine Announces Chief Financial Officer Transition (GlobeNewswire)
Mar-05-25 05:25PM	Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +16.48% -13.17%
04:19PM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates (GlobeNewswire)
Feb-24-25 09:00AM	Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March (GlobeNewswire)
Jan-14-25 09:30AM	Editas Medicine Outlines 2025 Strategic Priorities and Milestones (TipRanks)
Jan-13-25 09:00AM	Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities (GlobeNewswire) -7.94%
Jan-06-25 09:00AM	Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.72%
Dec-30-24 03:11PM	Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-14-24 07:01AM	Editas Medicine price target lowered to $8 from $10 at Baird (TipRanks)
Dec-13-24 02:15PM	Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% (Investing.com) -23.81%
01:26PM	Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts (GuruFocus.com)
06:44AM	Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 (Benzinga)
Dec-12-24 04:00PM	Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years (GlobeNewswire) -5.03%
12:37PM	Editas to lay off staff after search for sickle cell partner comes up empty (BioPharma Dive)
Dec-09-24 12:00PM	Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-24 11:30AM	Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? (Zacks)
Nov-26-24 06:50AM	Editas Medicine downgraded to Underperform from Buy at BofA (TipRanks) -7.14%
Nov-06-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.13%
Nov-05-24 01:59PM	Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty (GuruFocus.com) +8.33%
Nov-04-24 08:40AM	Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:36AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Editas Medicine Announces Third Quarter 2024 Results and Business Updates (GlobeNewswire)
Oct-31-24 03:55AM	Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? (Insider Monkey)
Oct-25-24 10:00AM	Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline (Zacks)
Oct-22-24 12:13PM	Editas and Genevant team up to develop gene editing therapies (Pharmaceutical Technology) -12.50%
07:15AM	Editas, changing course again, looks to partner lead CRISPR therapy (BioPharma Dive)
07:00AM	Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update (GlobeNewswire)
Oct-21-24 04:30PM	Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics (GlobeNewswire) +11.90%
Oct-18-24 04:01PM	Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept (GlobeNewswire)
Oct-17-24 05:01PM	State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings (GuruFocus.com)
Oct-05-24 06:27AM	Editas Medicine Secures $57M Deal for Gene-Editing Technology (TipRanks)

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Neill Gilmore Neil	CEO	Mar 03 '26	Sale	2.02	5,394	10,894	263,693	Mar 04 04:56 PM
Parison Amy	SVP, Chief Financial Officer	Mar 03 '26	Sale	2.02	474	957	15,434	Mar 04 04:49 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Mar 03 '26	Sale	2.02	749	1,513	68,028	Mar 04 04:48 PM
O'Neill Gilmore Neil	Officer	Mar 03 '26	Proposed Sale	1.89	6,000	11,340		Feb 27 04:35 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Dec 03 '25	Sale	2.15	713	1,535	68,777	Dec 04 04:39 PM
O'Neill Gilmore Neil	CEO	Dec 03 '25	Sale	2.15	5,603	12,064	269,087	Dec 04 04:38 PM
Parison Amy	SVP, Chief Financial Officer	Dec 03 '25	Sale	2.15	461	993	15,908	Dec 04 04:38 PM
O'Neill Gilmore Neil	Officer	Dec 03 '25	Proposed Sale	2.50	7,000	17,500		Dec 01 05:06 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Sep 03 '25	Sale	2.60	710	1,843	69,490	Sep 04 04:21 PM
Parison Amy	SVP, Chief Financial Officer	Sep 03 '25	Sale	2.60	458	1,189	16,369	Sep 04 04:20 PM
O'Neill Gilmore Neil	CEO	Sep 03 '25	Sale	2.60	5,592	14,517	274,690	Sep 04 04:20 PM
O'Neill Gilmore Neil	Officer	Sep 03 '25	Proposed Sale	2.73	7,000	19,110		Aug 29 04:34 PM
Burkly Linda	Officer	Sep 03 '25	Proposed Sale	2.73	800	2,184		Aug 29 04:22 PM
Parison Amy	SVP, Chief Financial Officer	Aug 07 '25	Sale	2.58	679	1,752	16,827	Aug 08 04:28 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 31 '25	Sale	2.49	5,121	12,757	64,398	Aug 04 04:49 PM
Burkly Linda	Officer	Jul 31 '25	Proposed Sale	3.46	7,500	25,950		Jul 30 04:15 PM
Parison Amy	SVP, Chief Financial Officer	Jun 03 '25	Sale	1.72	446	769	17,506	Jun 04 06:39 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jun 03 '25	Sale	1.72	726	1,252	69,519	Jun 04 06:37 PM
O'Neill Gilmore Neil	CEO	Jun 03 '25	Sale	1.72	15,192	26,196	280,282	Jun 04 06:36 PM
O'Neill Gilmore Neil	Officer	Jun 03 '25	Proposed Sale	1.87	20,000	37,400		Jun 02 05:32 PM

Open in Screener

XAIR

Beyond Air Inc

Apr 02 • 04:00PM ET

0.7096

-0.0046 -0.64 %

Healthcare • Medical Devices • USA • NASD

Peers: MDT ABT ISRG SYK BSX EW INSP PEN NVCR TMDX

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-5.42	Insider Own	5.88%	Shs Outstand	10.53M	Perf Week	2.84%
Market Cap	7.47M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	0.00%	Shs Float	9.91M	Perf Month	-18.15%
Enterprise Value	13.38M	PEG	-	EPS next Q	-0.54	Inst Own	13.95%	Short Float	1.15%	Perf Quarter	-2.26%
Income	-31.00M	P/S	1.08	EPS this Y	72.16%	Inst Trans	-1.13%	Short Ratio	0.02	Perf Half Y	-70.80%
Sales	6.92M	P/B	0.74	EPS next Y	54.47%	ROA	-87.43%	Short Interest	0.11M	Perf YTD	-2.26%
Book/sh	0.97	P/C	0.42	EPS next 5Y	51.60%	ROE	-240.75%	52W High	5.84 -87.85%	Perf Year	-85.88%
Cash/sh	1.70	P/FCF	-	EPS past 3/5Y	25.75% 17.29%	ROIC	-99.00%	52W Low	0.67 6.45%	Perf 3Y	-99.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 21.66%	Gross Margin	1.83%	Volatility	9.88% 8.05%	Perf 5Y	-99.36%
Dividend TTM	-	EV/Sales	1.93	EPS Y/Y TTM	74.30%	Oper. Margin	-419.51%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.77	Sales Y/Y TTM	129.04%	Profit Margin	-447.75%	RSI (14)	36.56	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	5.12	EPS Q/Q	71.23%	SMA20	-8.03%	Beta	0.47	Target Price	7.75
Payout	-	Debt/Eq	2.91	Sales Q/Q	104.66%	SMA50	-27.29%	Rel Volume	0.02	Prev Close	0.71
Employees	61	LT Debt/Eq	2.86	Earnings	Feb 13 BMO	SMA200	-62.99%	Avg Volume	7.43M	Price	0.71
IPO	Sep 23, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	-13.26% 1.89%	Trades		Volume	184,524	Change	-0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-17-25	Initiated	D. Boral Capital	Buy	$11
Jun-25-24	Downgrade	BTIG Research	Buy → Neutral
Jul-28-23	Initiated	Piper Sandler	Overweight	$10
Jun-15-23	Initiated	BTIG Research	Buy	$15
Apr-28-21	Initiated	Truist	Buy	$12
Oct-22-19	Initiated	Oppenheimer	Outperform	$9

Apr-01-26 09:00AM	Beyond Air Expands Commercial Access for LungFit PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO) (GlobeNewswire)
Mar-26-26 04:05PM	Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO (GlobeNewswire) -6.74%
Mar-17-26 04:35PM	Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial (GlobeNewswire)
Mar-11-26 07:00AM	Beyond Air to Participate in the 38th Annual Roth Conference in March (GlobeNewswire)
Mar-10-26 07:30AM	Beyond Air Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. (GlobeNewswire)
05:39AM	Loading…
Mar-04-26 05:39AM	Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies (Insider Monkey)
Feb-20-26 08:00PM	Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... (GuruFocus.com) -7.34%
08:00AM	Beyond Air Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections (GlobeNewswire)
Feb-13-26 04:32PM	Beyond Air, Inc. Q3 2026 Earnings Call Summary (Moby)
07:30AM	Beyond Air Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-04-26 08:00AM	Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 (GlobeNewswire) -5.22%
Jan-27-26 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -7.53% -5.93%
Jan-26-26 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire) -9.88%
Jan-14-26 08:30AM	Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -14.16%
Jan-13-26 01:40PM	Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments (Benzinga) +150.00%
07:30AM	Loading…
07:30AM	XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership (GlobeNewswire)
Dec-30-25 07:30AM	Beyond Air Appoints Dan Moorhead as Chief Financial Officer (GlobeNewswire)
Dec-17-25 07:30AM	Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Germany and Brazil (GlobeNewswire)
Nov-26-25 04:30PM	Beyond Air Announces Transition of Chief Financial Officer (GlobeNewswire)
Nov-11-25 12:02AM	Beyond Air Inc (XAIR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... (GuruFocus.com) -16.09%
Nov-10-25 04:05PM	Beyond Air Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-05-25 08:00AM	Beyond Air Secures Up to $32 Million to Accelerate Growth (GlobeNewswire)
Oct-23-25 08:00AM	Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire)
Sep-22-25 08:00AM	Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference (GlobeNewswire) +5.38%
Sep-08-25 03:55PM	Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds (GlobeNewswire) +49.77%
08:00AM	NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults (GlobeNewswire)
Sep-03-25 08:00AM	Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-20-25 08:00AM	Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Japan (GlobeNewswire) -6.55%
Aug-13-25 03:11AM	Beyond Air Inc (XAIR) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... (GuruFocus.com) -22.47%
Aug-12-25 05:35PM	Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Beyond Air Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:45AM	Beyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com) +5.33%
Aug-07-25 06:20PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +5.63%
Jul-25-25 08:00AM	Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire)
Jul-22-25 07:30AM	Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc. (GlobeNewswire)
Jun-26-25 09:55AM	Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher (Zacks) -6.47%
Jun-18-25 03:01AM	Beyond Air Inc (XAIR) (Q4 2025) Earnings Call Highlights: Revenue Soars Amidst Strategic Global ... (GuruFocus.com) -29.02%
Jun-17-25 05:15PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +58.69%
04:01PM	Beyond Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-16-25 09:16AM	Beyond Air Inc (XAIR) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:00AM	Beyond Air Submits FDA PMA Supplement for Next Generation LungFit PH (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
May-28-25 05:20PM	Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-20-25 08:00AM	Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-24-25 04:05PM	Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) (GlobeNewswire)
Apr-21-25 04:05PM	NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism (GlobeNewswire)
Apr-15-25 04:05PM	NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board (GlobeNewswire)
Apr-09-25 04:05PM	Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit GO at Home (GlobeNewswire) +11.63%
Apr-01-25 08:00AM	NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders (GlobeNewswire) -8.22%
Mar-31-25 08:00AM	Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site (GlobeNewswire)
Mar-24-25 04:05PM	NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy (GlobeNewswire) +5.63%
Mar-23-25 08:38AM	Beyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-11-25 07:30AM	Beyond Air Announces Agreements Expanding Global Distribution of LungFit PH (GlobeNewswire)
Mar-06-25 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -6.06%
Feb-10-25 04:05PM	Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.37% -6.49%
Feb-07-25 07:10AM	Beyond Air Inc (XAIR) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-05-25 09:29AM	Beyond Air Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Jan-27-25 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) -7.83%
Jan-24-25 09:15AM	Beyond Air Announces LungFit PH Receives Market Authorization in Australia (GlobeNewswire)
Jan-06-25 08:00AM	Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (GlobeNewswire)
Dec-03-24 04:05PM	Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy (GlobeNewswire) +7.85% -8.67%
Dec-02-24 07:30AM	Beyond Air Receives CE Mark in Europe for the LungFit PH System (GlobeNewswire)
Nov-26-24 07:30AM	NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board (GlobeNewswire) +22.16%
Nov-14-24 04:05PM	Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +9.71% -5.38%
Nov-11-24 04:05PM	Beyond Air Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.64%
07:00AM	Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-08-24 07:06AM	Beyond Air Inc (XAIR) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.86%
Oct-29-24 04:22PM	Beyond Air Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) +11.65% +8.78%
Oct-07-24 07:00AM	Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -5.45%
Oct-02-24 07:30AM	Beyond Air Partners with Healthcare Links to Expand Access to LungFit PH System Through Group Purchasing Organizations and Integrated Delivery Networks (GlobeNewswire) +10.57%
Sep-28-24 07:40AM	Beyond Air to sell 40.39M shares at 51c in private placement (TipRanks)
07:35AM	Beyond Air terminates loan, security agreements with Avenue Capital (TipRanks)
Sep-27-24 07:34AM	Beyond Air Provides LungFit PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed (GlobeNewswire)
07:32AM	Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital (GlobeNewswire)
07:30AM	Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Sep-23-24 08:00AM	Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire) -6.08%
Aug-06-24 04:05PM	Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -17.38%
Jul-31-24 04:15PM	Beyond Air Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia (GlobeNewswire) -5.16%
Jul-23-24 04:05PM	Beyond Air to Report First Fiscal Quarter 2025 Financial Results on August 6 (GlobeNewswire) +5.29%
Jul-16-24 04:05PM	Beyond Air To Participate in the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-10-24 09:55AM	Beyond Air (XAIR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +5.59%
Jun-26-24 08:01AM	Beyond Air, Inc. (NASDAQ:XAIR) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-25-24 10:31AM	Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock (InvestorPlace) -51.54%
08:28AM	Why Is Beyond Air (XAIR) Stock Down 22% Today? (InvestorPlace)
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-24-24 08:53PM	XAIR Stock Earnings: Beyond Air Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace) +8.06%
05:25PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Beyond Air Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-13-24 04:05PM	Beyond Air Appoints David Webster as Chief Commercial Officer (GlobeNewswire)
Jun-03-24 07:00AM	Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) (GlobeNewswire) -8.59%
May-23-24 04:09PM	Beyond Air Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -9.50%
May-01-24 07:00AM	Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
Mar-21-24 12:00PM	Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.84%
Mar-20-24 09:00AM	Beyond Air Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire)
Feb-13-24 08:51AM	Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript (Insider Monkey) -17.67%
Feb-12-24 04:05PM	Beyond Air Reports Financial Results for Third Quarter of Fiscal Year 2024 (GlobeNewswire) +14.97%
Jan-18-24 08:00AM	Beyond Air Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -5.02%
Dec-27-23 07:30AM	Beyond Cancer Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors (GlobeNewswire)
Dec-21-23 01:40AM	Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc (GuruFocus.com) +12.04%
Nov-15-23 04:05PM	Beyond Air To Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +23.57% -8.96%

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lisi Steven A.	CEO and Chairman of the Board	Jul 21 '25	Buy	3.25	6,000	19,491	3,327,411	Jul 23 04:05 PM

DYN

Dyne Therapeutics Inc

EDIT

Editas Medicine Inc

XAIR

Beyond Air Inc

Upgrade your Finviz experience